Patients with acute myeloid leukemia aged 65-75 have a very poor prognosis, irrespective of
the treatment strategy, including demethylating agents or conventional chemotherapy. With
these approaches, remission rates do not exceed 40%, and overall disease-free survival at 1
year is in the order of 15%. The hypothesis is that up-front allogeneic hematopoietic stem
cell transplant will produce a complete remission rate of 60% on day +56-70, and disease-free
survival at 1 year of 30%. This is a single arm phase II study of upfront allogeneic stem
cell transplantation, for patients with acute myeloid leukemia aged 65-75: the primary
endpoint is a complete remission rate on day +56-70. The secondary endpoint is a 1-year
overall disease-free survival of 30%.